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Abstract: Oxaliplatin, a third-generation platinum compound incorporating oxalate and 
1,2-diaminocyclohexane platinum, has been widely used in chemotherapy regimens for the 
treatment of metastatic colorectal cancer. Because of its wide spectrum of antitumor activity, 
oxaliplatin has been applied for the treatment of other carcinomas. However, the antitumor 
activity of single-agent oxaliplatin is insufficient. To increase its antitumor effects, polymeric 
micellar nanoparticles incorporating 1,2-diaminocyclohexane platinum (NC-4016) have been 
developed. The present study was designed to evaluate the efficacy of NC-4016 and its associa-
tion with peripheral neuropathy, which is a primary dose-limiting factor in oxaliplatin therapy. 
The in vitro antitumor activity of NC-4016 was investigated using human carcinoma cell lines. 
To investigate the antitumor effects of NC-4016 in vivo, nude mice bearing the human carci-
noma cell line KB were administered NC-4016 or oxaliplatin. The in vitro growth-inhibiting 
effect of NC-4016 was significantly weaker than that of oxaliplatin. However, the antitumor 
efficacy of NC-4016 was superior to that of oxaliplatin in vivo. Moreover, we compared 
the severity of peripheral neuropathy induced by oxaliplatin and NC-4016 in a rat model. 
 Oxaliplatin, NC-4016, or 5% glucose (control) were administered by a single tail vein injec-
tion. In the oxaliplatin-treated rats, neither mechanical nor heat allodynia was observed during 
the experimental period, whereas cold hyperalgesia/allodynia was observed from day 1 to 7. 
Conversely, cold hyperalgesia/allodynia was not observed in the NC-4016-treated rats. The 
present study demonstrated that the antitumor efficacy of NC-4016 was superior to that of 
oxaliplatin in a mouse model of human carcinoma cell line KB. In addition, NC-4016-treated 
rats did not develop acute cold hypersensitivity, which is frequently experienced by patients 
after oxaliplatin administration.
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Introduction
Oxaliplatin is a third-generation cisplatin derivative in which the chlorine and amine 
groups have been replaced with oxalate and 1,2-diaminocyclohexane platinum 
(DACH-Pt), respectively. Oxaliplatin has been widely used as a chemotherapeutic 
agent for the treatment of metastatic colorectal cancer.1 DACH-Pt possesses a wide 
spectrum of activity and is active against cisplatin (CDDP)-resistant tumors.2,3 There-
fore, oxaliplatin has been used for the treatment of other carcinomas, including gastric, 
pancreatic, ovarian, breast, and lung carcinomas, in many clinical trials. A Phase II 
study of single-agent oxaliplatin in 44 advanced head and neck squamous cell carci-
noma (HNSCC) patients showed an excellent side effect profile; however, the response 
rate was only 10%.4 On the other hand, the use of oxaliplatin combined with folinic 
acid and 5-fluorouracil in 36 advanced HNSCC patients showed a 61% response rate.5 





These results showed that the antitumor activity of 
single-agent oxaliplatin is insufficient. With respect to side 
effects, the incidence of nephrotoxicity and hematological 
toxicity with oxaliplatin was reportedly lower than that with 
other platinum (Pt)-based chemotherapeutic agents.6  However, 
severe peripheral neuropathy is induced by oxaliplatin therapy 
and often becomes a dose-limiting factor.7,8
Recently, several types of therapeutic nanoparticle plat-
forms, including liposomes, nanoparticles, and polymeric 
micelles, have been developed on the basis of the idea that 
these drug delivery systems can facilitate the selective accu-
mulation of chemotherapeutic drugs within the tumor, with 
decreased distribution to normal tissues and minimal 
undesirable side effects.9–11 Nishiyama and Kataoka, and 
Nishiyama et al developed several antitumor drug–
incorporating polymeric micellar nanoparticles, including 
NC-6004 and NC-4016.12,13 NC-6004 is a CDDP-incor-
porating polymeric micellar nanoparticle. Previously, we 
demonstrated that NC-6004 had more potential advantages, 
including greater antitumor activity, improved lymphatic 
drug delivery, and decreased nephrotoxicity, with regard 
to head and neck cancer treatment compared with CDDP 
alone.14 NC-4016 is a polymeric micellar nanoparticle devel-
oped by Cabral et al13 that incorporates DACH-Pt within the 
core. The solubility of DACH-Pt in water is much lower than 
that of CDDP (0.25 mg/mL versus 1.2 mg/mL);15 therefore, 
DACH-Pt needs oxalate to enhance its solubility in water. 
By contrast, the NC-4016 micelles were prepared through 
polymer–metal complex formation between DACH-Pt and 
poly(ethylene glycol)–poly(glutamic acid) block copolymers 
(PEG-P(Glu)) in distilled water after converting DACH-Pt 
to its aqueous complex by pretreatment with the silver (2+) 
salt (2:1) silver nitrate (AgNO3) to increase its solubility in 
water. In addition to water solubility, PEG-P(Glu) confers 
considerable stability and has a diameter of 40 nm, which 
may be sufficient to achieve extended blood circulation, 
avoid uptake by the reticuloendothelial system, and over-
come the permeation barrier of poorly permeable tumors. 
This mechanism has been recognized as the “enhanced 
permeability and retention” effect, in which extravasated 
high-molecular-weight micelles pass through leaky tumor 
capillary fenestrations resulting from abnormalities in angio-
genesis at the tumor site, thus leading to accumulation and 
retention of the particles for prolonged durations.13
In the present study, we analyzed the antitumor effect of 
NC-4016 in a mouse model of human carcinoma cell line 
KB. In addition, we compared NC-4016 with oxaliplatin in 
a rat model of peripheral neuropathy, which is a primary 
dose-limiting factor in oxaliplatin therapy.
Materials and methods
In vitro growth inhibition assay
Oxaliplatin was obtained from Wako Pure Chemical 
 Industries, Ltd. (Osaka, Japan), while NC-4016 was supplied 
by NanoCarrier Co., Ltd. (Chiba, Japan). The human oral car-
cinoma cell lines, KB, OSC-19 (human squamous cell carci-
noma cell line from tongue), OSC-20 (human squamous cell 
carcinoma cell line from tongue metastasized to neck lymph 
node), HSC-3 (human oral squamous carcinoma cell line with 
high metastatic potential), and HSC-4 (human squamous 
carcinoma cell line from tongue) were used in the present 
study. The KB cell lines were kindly provided by Shin-ichi 
Akiyama.16 KB is now known to be a subline of the ubiquitous 
keratin-forming tumor cell line HeLa (http://www.ncbi.nlm.
nih.gov/mesh?Db=mesh&term=KB+Cells). The KB, HSC-3, 
and HSC-4 cells were maintained in Dulbecco’s Modified 
Eagle’s Medium supplemented with 10% fetal bovine 
serum and 1% antibacterial agent, whereas the OSC-19 and 
OSC-20 cells were maintained in Eagle’s Minimum Essential 
Medium supplemented with 10% fetal bovine serum and 
1% antibacterial agent. The A-3-(4,5-dimethylthiazol- 
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium salt (MTS) assay was performed to assess the 
effects of cell proliferation, using the CellTiter 96® AQue-
ous One Solution Cell Proliferation Assay (Promega Corp, 
Fitchburg, WI, USA). Briefly, cells were seeded in 96-well 
culture plates at a density of 2×103 cells/well. After a 24-hour 
incubation period with either 5% glucose (control), a graded 
concentration of oxaliplatin, or NC-4016, the MTS reagents 
were added to each well and incubated for 48 or 72 hours. 
Optical density was read with an EMax Endpoint Elisa 
Microplate Reader (Molecular Devices LLC, Sunnyvale, 
CA, USA) at a wavelength of 490 nm. The half maximal 
inhibitory concentration (IC
50
) values represented drug con-
centrations that decreased the mean absorbance at 490 nm 
to 50% of that in the untreated control well.
evaluation of antitumor activity
Six-week-old female BALB/c-nu/nu mice (Charles River 
Laboratories, Inc., Wilmington, MA, USA) were subcuta-
neously inoculated with KB cells (1×105). After 14 days, 
the tumor diameters reached approximately 10 mm, and the 
tumor-bearing mice were randomly allocated to three drug 
administration groups: a control (5% glucose solution) group, 
an oxaliplatin (4 mg/kg body weight [BW], the equivalent 
of 1.96 mg/kg BW of elemental Pt) treatment group, and an 
NC-4016 (the equivalent of 1.96 mg/kg BW of Pt) treatment 
group. The drugs were intravenously injected via the tail vein 
at 14, 21, and 28 days after tumor transplantation.
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The major and minor axes of tumor were measured 
weekly. The tumor volume was calculated using the 
formula:
 tumor volume (mm3) = 1/2 × L × W2,  [1]
where L is the major axis and W is the minor axis.17,18 The 
mice were sacrificed on posttransplantation day 35, and the 
tumors were excised and weighed.
Plasma platinum concentration  
and tumor platinum accumulation
In the same manner as described above, 6-week-old female 
BALB/c-nu/nu mice were subcutaneously inoculated with 
KB cells. After 14 days, a single dose of either oxalipla-
tin or NC-4016 was intravenously administered at a dose 
of 1.96 mg/kg elemental Pt. Then, the mice were sacrificed 
at defined time periods (1, 24, 48, and 168 hours), and the 
tumors were excised. Blood samples were collected from 
the inferior vena cava and heparinized and centrifuged to 
obtain plasma. The plasma and tumor Pt concentrations were 
measured using atomic absorption spectrometry (NAC Co., 
Ltd., Tokyo, Japan).
assessment of drug-induced  
peripheral neuropathy
experimental animals
Young adult male Sprague–Dawley rats (BW 200–250 g) 
were purchased from Charles River Laboratories, Inc.) and 
housed in a temperature-controlled room (23°C) under a 
12-hour light–dark cycle, with ad libitum access to food 
and water.
ethics statement
This study was conducted under the auspices of the Local 
Animal Ethics Committee in accordance with the Regulations 
for Animal Experiments in the Kanazawa University Graduate 
School of Medicine (permit numbers: 122433 and 122465), 
the Act on Welfare and Management of Animals adopted 
by the Government of Japan (http://www.cas.go.jp/jp/
seisaku/hourei/data/AWMA.pdf), and the guidelines of the 
International Association for the Study of Pain (http://www.
iasp-pain.org/). All surgery was performed under sodium 
pentobarbital anesthesia, and all efforts were made to 
minimize animal suffering.
Oxaliplatin and Nc-4016 administration
The rats were divided into three treatment groups (oxali-
platin; NC-4016; and 5% glucose, as a control).  Oxaliplatin 
or NC-4016 was dissolved in 5% glucose solution and 
 administered to the respective rats via a single intravenous 
injection at a dose of 4 mg/kg BW (4.0 mL/kg volume, 
the equivalent of 1.96 mg/kg BW of Pt) to the tail vein. 
The control group was injected with the same volume of 5% 
glucose solution, calculated according to the BW of each 
animal (4 mL/kg).
Behavioral testing
Behavioral analyses were conducted by experimenters 
blinded to the experimental conditions.
acetone test
The acetone test was performed before and on days 1, 
2, 3, 5, 7, 9, and 14 after drug administration. Briefly, 
each animal was placed in a transparent plastic box with 
a wire mesh floor, and a drop (0.05 mL) of acetone was 
applied to the center of the plantar surface of the hind 
paw. The response of the rat was monitored for the follow-
ing 40  seconds and graded on a four-point scale defined by 
Flatters and Bennett. This was scored as:19 0= no response; 
1= quick withdrawal, flick, or stamp of the paw; 2= prolonged 
withdrawal or repeated flicking of the paw; and 3= repeated 
flicking of the paw with licking directed at the plantar sur-
face of the paw. Acetone was applied alternately to each 
hind paw for a total of three times, and the responses were 
scored. Cumulative scores were then generated by adding the 
six scores for each rat, yielding a minimum score of 0 and 
a maximum score of 18.
assessment of cold and heat allodynia
Conscious rats were gently wrapped with a string cover, 
and thermal stimulation was applied using a Peltier probe 
controller (UDH-300; Unique Medical Co., Ltd, Tokyo, 
Japan). The tip of the probe (5×5 mm) was applied to the 
plantar surface of the hind paw. Then, the temperature was 
serially increased from 30°C to 55°C (+1.0°C/s) or decreased 
from 30°C to 5°C (−1.0°C/s). Before measurement, the probe, 
at 30°C, was applied to the hind paw for at least 60 seconds. 
The temperature that induced paw withdrawal was mea-
sured as a nociceptive thermal threshold. Each animal was 
tested 10 times, at 5-minute intervals.
assessment of mechanical allodynia
The von Frey test was performed before and on days 1, 3, 6, 10, 
and 13 after drug administration. Briefly, each rat was 
placed in a cage with an elevated metal floor covered with 
transparent plastic boxes and allowed to acclimatize to 
the novel surroundings for at least 20 minutes prior to the 





initiation of behavioral testing. Then, the paw withdrawal 
threshold value was measured using a von Frey–type fila-
ment ( diameter 0.5 mm), by applying increasing force to the 
plantar surface of the hind paw, starting below the detection 
threshold and increasing until the animal withdrew its paw 
(Dynamic Plantar Aesthesiometer; Ugo Basile Srl, Comerio, 
Italy). The force was registered automatically, in grams, 
when the paw was withdrawn. A 50 g limit was imposed as 
the cutoff to preclude tissue damage. Each animal was tested 
five times at 5-minute intervals, and the five measurements 
were averaged.
statistical analysis
All data are expressed as means ± standard error of the mean. 
The values were analyzed using two-way repeated-measures 
analysis of variance (ANOVA) followed by the Bonferroni 
post hoc test, to determine differences among groups. SPSS 
statistical software (Version 18; IBM, Armonk, NY, USA) 
was used for all analyses. A P-value of 0.05 was considered 
statistically significant.
Results
sensitivity of human carcinoma cell lines 
to oxaliplatin and Nc-4016
The cytotoxicity of NC-4016 was compared with that of 
oxaliplatin, in human carcinoma cell lines: IC
50
 values were 
calculated from dose-survival curves obtained from MTS 
assays performed 48 and 72 hours after treatment. A graphical 
representation of the MTS assay of the KB cells is presented 
(Figure 1). The IC
50
 values for oxaliplatin were 15.2–78.4 µM 
at 48 hours and 5.2–69.2 µM at 72 hours. NC-4016 showed a 
lower range of growth inhibition compared with oxaliplatin, 
with IC
50
 values of 63.8–771.2 µM at 48 hours and 
13.6–334.2 µM at 72 hours. The cytotoxicity of oxaliplatin 
in vitro was 1.2- to 9.8-fold greater than that of NC-4016.
antitumor activity in KB xenografts
The antitumor activity of oxaliplatin and NC-4016 was a 
evaluated in mice with oral carcinoma. All mice in each 
group received a single intravenous injection of the respective 
drug or glucose, via the tail vein, on days 14, 21, and 28 after 
transplantation. All mice survived the experiment. All treat-
ments did not reduce body weight.
In the oxaliplatin and NC-4016 treatment groups, 
the tumor volume was significantly decreased compared 
with that in the control group, from 1 week after initial 
drug administration in the NC-4016 treatment group 
and from 2 weeks after initial drug administration in the 
oxaliplatin treatment group (Figure 2A). On day 35, tumor 
growth was  significantly lower in the NC-4016 group 
than in the control group (Figure 2B) (−74% [1.41±0.44 g 
versus 3.82±1.05 g]) (P=0.000). Similarly, tumor growth 
in the oxaliplatin group was also significantly lower than 
that in the control group (Figure 2B) (−33% [2.54±1.05 g 
versus 3.82±1.05 g]) (P=0.003). In addition, there was a 
significant difference in tumor growth inhibition between the 
NC-4016 and oxaliplatin groups (Figure 2B) (P=0.009).
Platinum concentration in the plasma  
and tumor after Nc-4016 treatment
The time course of elemental Pt concentration in the plasma 
and tumor after intravenous administration of either oxali-
platin or NC-4016 was measured (Figure 3). Plasma con-
centration and tumor accumulation of Pt after administration 
of NC-4016 peaked at 1 hour and 48 hours, respectively. 
Pt was rapidly cleared from circulation in the oxaliplatin 
group. Areas under the curve at 0–168 hours for plasma and 
tumor Pt concentrations in the NC-4016 group were signifi-
cantly higher than those in the oxaliplatin group. However, 
on day 7 (168 hours), plasma and tumor Pt concentrations 
were undetectable in both groups.
Behavioral testing
cold hyperalgesia/allodynia
In the acetone test, oxaliplatin significantly increased the cold 
sensitivity score compared with that in the control group on 

































Cell line IC50  (µM)
48 hours 72 hours
Oxaliplatin NC-4016 Oxaliplatin NC-4016
KB 30.5 85.6 14.2 30.2
OSC-19 78.4 771.2 69.2 334.3
OSC-20 60.2 510.2 55.3 276.5
HSC-3 15.2 90.6 5.2 13.6
HSC-4 18.6 63.8 17.6 21.6




























































Figure 2 effects of oxaliplatin or Nc-4016 in KB mouse models.
Notes: each data point is the mean value (± seM) of the largest tumor diameter (A). On day 35, the tumor was excised and weighed (B). Data were analyzed using a one-way 
(A) or two-way repeated-measures (B) aNOVa, followed by the Bonferroni post hoc test. *P0.05, **P0.01 compared with 5% glucose (control).






























































Figure 3 The time course of elemental platinum concentrations in the plasma (A) and tumor (B), after intravenous administration of oxaliplatin (4 mg/kg) or Nc-4016 (an 
equivalent dose to 4 mg/kg).
Notes: each drug was administered to KB-bearing nude mice (female, n=4). Data are presented as mean ± seM.
Abbreviation: seM, standard error of the mean.
days 1, 2, 3, 5, and 7 after single drug injection (Figure 4A), 
whereas NC-4016 did not. Similarly, the oxaliplatin-treated 
rats exhibited a significantly higher threshold temperature 
for withdrawal from cold stimuli compared with the control 
rats on day 1 through at least day 5 (Figure 4B), whereas the 
NC-4016-treated rats did not.
heat sensitivity
Heat sensitivity in the hind paws was evaluated following 
single drug injection. No change in the withdrawal threshold 
was observed during the 2 weeks in all groups (Figure 4C).
Mechanical sensitivity
Mechanical sensitivity of the hind paws was evaluated using 
the von Frey test following single drug injection. No change 
in the withdrawal threshold was observed during the 2 weeks 
in all groups (Figure 4D).
Discussion
The in vitro growth-inhibiting effect of the DACH-Pt-loaded 
micelle NC-4016 was significantly weaker than that of 
oxaliplatin, probably because of the slow-release behavior 
of DACH-Pt complexes from the micelles. The slow-release 
profile of Pt complexes from the DACH-Pt-loaded micelles 
was presented in the previous physicochemical study.13,20 In 
addition to the in vitro assay, we evaluated the in vivo anti-
tumor activity of oxaliplatin and NC-4016 in a mouse model 
of human carcinoma. Decreases in tumor weights after the 
administration of NC-4016 and oxaliplatin were approxi-
mately 74% and 33%, respectively, with a significant differ-
ence between them. The findings suggest that the antitumor 
effect of NC-4016 against human carcinoma cell lines is more 
potent than that of oxaliplatin in vivo, but not in vitro.
In the present study, NC-4016 resulted in high 
and extended Pt concentrations within the tumors. Pt 
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Figure 4 changes in cold sensitivity score (A), cold threshold temperature (B), heat threshold temperature (C), and mechanical threshold (D), following administration of 
either oxaliplatin, Nc-4016, or 5% glucose (control).
Notes: Data are presented as mean ± seM. Data were analyzed using a two-way repeated-measures aNOVa, followed by the Bonferroni post hoc test. *P0.05, **P0.01 
compared with 5% glucose (control).
Abbreviations: aNOVa, analysis of variance; seM, standard error of the mean.
concentration in the tumor decreased continuously with 
 oxaliplatin, while it decreased after initial increase with 
NC-4016. This is worthy of note. In addition, the previous 
study showed that NC-4016 preferentially accumulates within 
the tumor tissue compared with other tissue.20,21 Higher Pt 
concentrations in the tumor may indicate a stronger antitumor 
effect of NC-4016 compared with that of oxaliplatin in vivo.
Oxaliplatin lacks the nephrotoxicity associated with 
cisplatin, and the severe myelosuppression associated with 
carboplatin;22 however, it may induce severe peripheral neu-
ropathy. Severe oxaliplatin-induced peripheral neuropathy 
is characterized by two types of neurological symptoms. 
The first, acute neuropathy, occurs within hours after infu-
sion in 90% of patients and includes acral paresthesia and 
dysesthesia triggered or enhanced by exposure to cold. This 
type of neuropathy has not been observed before with other 
Pt-based agents; therefore, it may be a specific effect of 
oxaliplatin.
The other is chronic neuropathy, which is characterized 
by the loss of sensory and motor function after long-term 
oxaliplatin treatment. Chronic neuropathy is similar to 
cisplatin-induced neurological symptoms.23
A rat and mouse model of oxaliplatin-induced neuropathic 
pain was developed by Ling et al through repetitive intra-
venous injections of oxaliplatin.24 Assessment of cold and 
heat allodynia with the Peltier probe controller (UDH-300) 
was impossible in a mouse model. Therefore, we assessed 
a rat model of oxaliplatin-induced neuropathic pain in the 
present study. Acute cold hypersensitivity was not produced 
by other Pt-based chemotherapeutic agents, which are 
known to induce chronic peripheral neuropathy following 
repeated administration. Therefore, oxaliplatin, NC-4016, or 
5% glucose (control) were administered by a single intrave-
nous injection, via the tail vein, to assess pure acute peripheral 
neuropathy. In rats treated with oxaliplatin, neither mechani-
cal nor heat allodynia was observed during the behavioral 
experiments, whereas cold hyperalgesia/allodynia was 
observed from days 1 to 7. In the previous study, repeated 
administration of oxaliplatin caused cold hyperalgesia in 
the early phase and mechanical allodynia in the late phase 
(2 weeks after first administration).25–27 Conversely, cold 
hyperalgesia/allodynia was not observed in the NC-4016-
treated rats. Oxalate is well known as a chelator of both Ca2+ 
and Mg2+. In a recent clinical study, Ca2+ and Mg2+ infusions 
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were shown to decrease oxaliplatin-induced neuropathy 
 without affecting anticancer efficacy.28 Furthermore, recent 
evidence using an in vitro electrophysiological method showed 
that oxalate blocked voltage-gated Na+ channels.29 There-
fore, the lack of oxalate in NC-4016 may contribute to the 
decreased cold hyperalgesia/allodynia. The slow-release 
behavior of DACH-Pt complexes from the micelles may also 
decrease the incidence of acute neuropathy.
In the present study, we did not examine the effects of 
repeated injections of oxaliplatin and NC-4016. Therefore, our 
model is insufficient to assess chronic peripheral neuropathy. 
However, with repeated administration, acute symptoms may 
increase in both duration and severity, and patients may expe-
rience symptoms of acute and chronic neuropathy. Although 
the symptoms associated with acute peripheral sensory and 
motor nerve hyperexcitability seem to be transient in nature, 
those of chronic neuropathy can be distressing.
In conclusion, the present study demonstrated that the 
antitumor efficacy of NC-4016 was superior to that of oxali-
platin in a mouse model of human carcinoma cell line KB. 
In addition, the incidence of acute neuropathy symptoms, 
which has been frequently experienced by patients after 
oxaliplatin administration, was lower with NC-4016 than 
with oxaliplatin, in the rat model. Currently, the efficacy of 
NC-4016 is being assessed in a Phase I clinical trial.
Acknowledgments
The KB cells were provided by Shin-ichi Akiyama, Shigeru 
Oiso, and Tatsuhiko Furukawa. This work was supported by 
the Japan Society for the Promotion of Science KAKENHI 
(grant numbers 22791579 and 2365972) and a Grant for 
Clinical Cancer Research from the Ministry of Health, 
Labour and Welfare of Japan.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Kidani Y, Noji M, Tashiro T. Antitumor activity of platinum (II) comp-
lexes of 1,2-diamino-cyclohexane isomers. Gann. 1980;71(5):637–643.
2. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, 
and carboplatin: spectrum of activity in drug-resistant cell lines and in 
the cell lines of the National Cancer Institute’s Anticancer Drug Screen 
panel. Biochem Pharmacol. 1996;52(12):1855–1865.
3. Tashiro T, Kawada Y, Sakurai Y, Kidani Y. Antitumor activity of a 
new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)
platinum (II): new experimental data. Biomed Pharmacother. 1989; 
43(4):251–260.
4. Degardin M, Cappelaere P, Krakowski I, Fargeot P, Cupissol D, 
Brienza S. Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent 
and/or metastatic squamous cell carcinoma of the head and neck. Eur J 
Cancer B Oral Oncol. 1996;32B(4):278–279.
 5. Raguse JD, Gath HJ, Oettle H, Bier J. Oxaliplatin, folinic acid and 
5-fluorouracil (OFF) in patients with recurrent advanced head and neck 
cancer: a phase II feasibility study. Oral Oncol. 2006;42(6):614–618.
 6. Desoize B, Madoulet C. Particular aspects of platinum compounds 
used at present in cancer treatment. Crit Rev Oncol Hematol. 2002; 
42(3):317–325.
 7. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and 
molecular basis of oxaliplatin neurotoxicity: current management 
and development of preventive measures. Semin Oncol. 2002;29 
(5 Suppl 15):21–33.
 8. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003; 
30(4 Suppl 15):5–13.
 9. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an 
emerging treatment modality for cancer. Nat Rev Drug Discov. 
2008;7(9):771–782.
 10. Torchilin VP. Recent advances with liposomes as pharmaceutical car-
riers. Nat Rev Drug Discov. 2005;4(2):145–160.
 11. Nishiyama N, Kataoka K. Current state, achievements, and future pros-
pects of polymeric micelles as nanocarriers for drug and gene delivery. 
Pharmacol Ther. 2006;112(3):630–648.
 12. Nishiyama N, Okazaki S, Cabral H, et al. Novel cisplatin-incorporated 
polymeric micelles can eradicate solid tumors in mice. Cancer Res. 
2003;63(24):8977–8983.
 13. Cabral H, Nishiyama N, Okazaki S, Koyama H, Kataoka K. Prepara-
tion and biological properties of dichloro(1,2-diaminocyclohexane)
platinum (II) (DACHPt)-loaded polymeric micelles. J Control Release. 
2005;101(1–3):223–232.
 14. Endo K, Ueno T, Kondo S, et al. Tumor-targeted chemotherapy with the 
nanopolymer-based drug NC-6004 for oral squamous cell carcinoma. 
Cancer Sci. 2013;104(3):369–374.
 15. Kidani Y, Inagaki K, Iigo M, Hoshi A, Kuretani K. Antitumor activity 
of 1,2-diaminocyclohexane – platinum complexes against sarcoma-180 
ascites form. J Med Chem. 1978;21(12):1315–1318.
 16. Fujii R, Mutoh M, Niwa K, et al. Active efflux system for cisplatin 
in cisplatin-resistant human KB cells. Jpn J Cancer Res. 1994;85(4): 
426–433.
 17. Nathan CO, Amirghahari N, Rong X, et al. Mammalian target of rapamy-
cin inhibitors as possible adjuvant therapy for microscopic residual dis-
ease in head and neck squamous cell cancer. Cancer Res. 2007;67(5): 
2160–2168.
 18. Carlsson G, Gullberg B, Hafström L. Estimation of liver tumor volume 
using different formulas – an experimental study in rats. J Cancer Res 
Clin Oncol. 1983;105(1):20–23.
 19. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and 
vincristine-induced painful peripheral neuropathy. Pain. 2004;109(1–2): 
150–161.
 20. Cabral H, Nishiyama N, Kataoka K. Optimization of (1,2-diamino-
cyclohexane) platinum (II)-loaded polymeric micelles directed to 
improved tumor targeting and enhanced antitumor activity. J Control 
Release. 2007;121(3):146–155.
 21. Yamamoto Y, Hyodo I, Takigahira M, et al. Effect of combined 
treatment with the epirubicin-incorporating micelles (NC-6300) 
and 1,2-diaminocyclohexane platinum (II)-incorporating micelles 
(NC-4016) on a human gastric cancer model. Int J Cancer. 2014;135(1): 
214–223.
 22. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety 
profile of oxaliplatin. Semin Oncol. 1998;25(2 Suppl 5):S13–S22.
 23. Pasetto LM, D’Andrea MR, Rossi E, Monfardini S. Oxaliplatin-
related neurotoxicity: how and why? Crit Rev Oncol Hematol. 2006; 
59(2):159–168.
 24. Ling B, Authier N, Balayssac D, Eschalier A, Coudore F. Behavioral and 
pharmacological description of oxaliplatin-induced painful neuropathy 
in rat. Pain. 2007;128(3):225–234.
 25. Sakurai M, Egashira N, Kawashiri T, Yano T, Ikesue H, Oishi R. 
Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in 
cold hyperalgesia but not mechanical allodynia. Pain. 2009;147(1–3): 
165–174.
International Journal of Nanomedicine 2014:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
 MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/




 26. Kawashiri T, Egashira N, Watanabe H, et al. Prevention of oxaliplatin-
induced mechanical allodynia and neurodegeneration by neurotropin 
in the rat model. Eur J Pain. 2011;15(4):344–350.
 27. Norcini M, Vivoli E, Galeotti N, Bianchi E, Bartolini A, Ghelardini C. 
Supraspinal role of protein kinase C in oxaliplatin-induced neuropathy 
in rat. Pain. 2009;146(1–2):141–147.
 28. Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-
related neurotoxicity by calcium and magnesium infusions: a retro-
spective study of 161 patients receiving oxaliplatin combined with 
5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin 
Cancer Res. 2004;10(12 Pt 1):4055–4061.
 29. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, 
Gamelin E. A possible explanation for a neurotoxic effect of the anti-
cancer agent oxaliplatin on neuronal voltage-gated sodium channels. 
J Neurophysiol. 2001;85(5):2293–2297.
